Patents by Inventor Shouchun Liu

Shouchun Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240218317
    Abstract: An application of Bacillus velezensis HL-5 capable of improving an extraction rate of heparin in aquatic products, the Bacillus velezensis HL-5 is preserved in Guangdong Microbial Culture Collection Center on Jul. 2, 2018, with a preservation number of GDMCC No.: 60403, which is applied to extract heparin from shellfish. Compared with a conventional enzymolysis method, the extraction rate of the heparin is increased by 10.55%-72.07%. The Bacillus velezensis HL-5 has a stronger capability of producing lipase and protease, and has a good application prospect in the extraction of the heparin of aquatic products.
    Type: Application
    Filed: March 24, 2022
    Publication date: July 4, 2024
    Inventors: Saiyi ZHONG, Huanming LIU, Shouchun LIU, Pengzhi HONG, Chujin DENG
  • Patent number: 11890354
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: February 6, 2024
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Publication number: 20220289853
    Abstract: The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 22, 2021
    Publication date: September 15, 2022
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu
  • Patent number: 11180562
    Abstract: The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: November 23, 2021
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu
  • Publication number: 20210309727
    Abstract: The invention relates generally to activatable antibodies and methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: December 8, 2020
    Publication date: October 7, 2021
    Inventors: Henry Bernard LOWMAN, Shouchun LIU
  • Publication number: 20210023243
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: June 4, 2020
    Publication date: January 28, 2021
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Patent number: 10894821
    Abstract: The invention relates generally to activatable antibodies and methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 19, 2021
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Henry Bernard Lowman, Shouchun Liu
  • Publication number: 20200270350
    Abstract: The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: December 12, 2019
    Publication date: August 27, 2020
    Inventors: Henry Bernard LOWMAN, Luc Roland Desnoyers, Shouchun Liu
  • Patent number: 10709799
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: July 14, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Patent number: 10533053
    Abstract: The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 14, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu
  • Publication number: 20180333507
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: January 19, 2018
    Publication date: November 22, 2018
    Inventors: Henry Bernard LOWMAN, Luc Roland DESNOYERS, Shouchun LIU, James William WEST, Jason Gary SAGERT, Olga VASILJEVA, Elizabeth-Edna Mary MENENDEZ
  • Publication number: 20180298085
    Abstract: The invention relates generally to activatable antibodies and methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: December 13, 2017
    Publication date: October 18, 2018
    Inventors: Henry Bernard Lowman, Shouchun Liu
  • Patent number: 9889211
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: February 13, 2018
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Patent number: 9856314
    Abstract: The invention relates generally to activatable antibodies and methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: January 2, 2018
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Shouchun Liu
  • Publication number: 20170196996
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: December 16, 2016
    Publication date: July 13, 2017
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Publication number: 20170096489
    Abstract: The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu
  • Patent number: 9545442
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: January 17, 2017
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Patent number: 9540440
    Abstract: The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: January 10, 2017
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu
  • Publication number: 20160193332
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: July 31, 2015
    Publication date: July 7, 2016
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Patent number: 9120853
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: September 1, 2015
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Henry Bernard Lowman, Luc Roland Desnoyers, Shouchun Liu, James William West, Jason Gary Sagert, Olga Vasiljeva, Elizabeth-Edna Mary Menendez